COMMUNIQUÉS West-GlobeNewswire

Kalytera Confirms No Material Change in Operations
05/12/2017
SAN FRANCISCO and TEL AVIV, Israel, Dec. 05, 2017 (GLOBE NEWSWIRE) -- At the request of IIROC, Kalytera Therapeutics, Inc. (TSX-V: KALY ) (OTCQB:KALTF) (the " Company " or " Kalytera ") wishes to confirm that the [...]
ABILITY Network Helps Skilled Nursing Providers Streamline the Triple Check Process
05/12/2017
MINNEAPOLIS, Dec. 05, 2017 (GLOBE NEWSWIRE) -- ABILITY Network, a leading information technology company, today announced that it has added a powerful capability to its ABILITY | UBWATCH application to help streamline [...]
Texas Health IT company wants to make the US healthcare market competitive again
05/12/2017
HOUSTON, Dec. 05, 2017 (GLOBE NEWSWIRE) -- By creating a secure platform for people to store their health records and shop for medical providers, one new company out of Houston plans to revitalize the American [...]
RedHill Biopharma Provides 2017 Year-End Business Update
05/12/2017
TEL-AVIV, Israel and RALEIGH, N.C., Dec. 05, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ: RDHL ) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily [...]
Transactions concluded by management
05/12/2017
Olaine, 2017-12-05 15:21 CET (GLOBE NEWSWIRE) -- AS Olainfarm has received the notification of manager on transactions with securities issued by AS Olainfarm. The received notification is available in attachment. [...]
Adverum Biotechnologies Begins Patient Enrollment in the ADVANCE Phase 1/2 Clinical Trial for A1AT Deficiency
05/12/2017
-- Patients to Receive Single-administration of Gene Therapy Candidate ADVM-043 -- -- Company Expects to Report Preliminary Data in the Second Half of 2018 -- MENLO PARK, Calif., Dec. 05, 2017 (GLOBE NEWSWIRE) -- [...]
Chembio Receives $8.5 Million Commitment from Bio-Manguinhos to Purchase Components for Production of DPP® Assays in Brazil during 2018
05/12/2017
MEDFORD, N.Y., Dec. 05, 2017 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI ), a leader in point-of-care (POC) diagnostic tests for infectious diseases, today announced that it has received an $8.5 million [...]
Mateon Announces Preclinical Data Indicating Enhanced Tumor Immune Response of CA4P with Checkpoint Inhibitor
05/12/2017
Addition of CA4P simultaneously reduces tumor volume and increases tumor white blood cells, T Cells and cytotoxic T Cells compared to anti-CTLA-4 monotherapy Preliminary data suggest immuno-oncology applications for [...]
CV Sciences, Inc. Repays Installment Obligation on Convertible Debt
05/12/2017
LAS VEGAS, Dec. 05, 2017 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our” or “we”) announced today that it has paid the December 2017 installment obligation under its March 1, 2017 [...]
Novan Announces First Patient Dosed in Phase 1b Atopic Dermatitis Trial with SB414
05/12/2017
MORRISVILLE, N.C., Dec. 05, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ: NOVN ) today announced that the first patient has been dosed in the Company's Phase 1b clinical trial to evaluate [...]
Antibacterial Benefits of PEKK for Orthopedic Applications Detailed in Study of 3D-Printed OsteoFab® Structures
05/12/2017
SOUTH WINDSOR, Conn., Dec. 05, 2017 (GLOBE NEWSWIRE) -- Oxford Performance Materials, Inc. (OPM), a leader in advanced materials science and high performance additive manufacturing (HPAM™), today announced the results [...]
Fortress Biotech Forms Subsidiary Tamid Bio to Develop Novel AAV Gene Therapies in Orphan Diseases With Unmet Medical Needs
05/12/2017
NEW YORK, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO ) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology [...]
Sarepta Therapeutics Elects Biopharmaceutical Veteran, Michael W. Bonney, to its Board of Directors
05/12/2017
CAMBRIDGE, Mass., Dec. 05, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT ), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to [...]
100% of Prostate Cancer Patients Completing 31-Week Post-Therapy Exam After Treatment with OncBioMune Immunotherapy Show No Disease Progression
05/12/2017
BATON ROUGE, La., Dec. 05, 2017 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of a proprietary [...]
Galectin Therapeutics Announces Results from Phase 2b NASH-CX Trial
05/12/2017
Statistically significant and clinically meaningful effects observed in NASH cirrhosis patients without esophageal varices treated with GR-MD-02 Conference Call at 8:30 A.M. ET to Present Top Line Trial Results NORCROSS [...]
BIOLIFE4D Comments on New Guidelines for High Blood Pressure in Adults
05/12/2017
CHICAGO, Dec. 05, 2017 (GLOBE NEWSWIRE) -- BIOLIFE4D , a biotech pioneer leveraging advances in tissue engineering to 3D print human organs viable for transplant, today commented on a new report from the American [...]
Tyme Provides Update on At-The-Market Financing Activity
05/12/2017
NEW YORK, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (Nasdaq: TYME ), a clinical-stage biotechnology company developing cancer therapeutics, announced it has raised gross proceeds of approximately $5.0 [...]
Ovid Therapeutics Announces TAK-935/OV935 Has Received Orphan Drug Designation from U.S. FDA for Treatment of Dravet Syndrome
05/12/2017
NEW YORK, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID ), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today [...]
CRISPR Therapeutics Announces Oral Presentation of New Data on CTX001, a CRISPR Gene-Edited Medicine for β-Thalassemia and Sickle Cell Disease, at the ASH Annual Meeting
05/12/2017
ZUG, Switzerland and CAMBRIDGE, Mass., Dec. 05, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP ) today announced that Dr. Bill Lundberg, Chief Scientific Officer of CRISPR, is scheduled to present new data [...]

Pages